ARTICLE | Clinical News
Neuro-Hitech falls on AD data
February 2, 2008 2:01 AM UTC
Neuro-Hitech (NASDAQ:NHPI) fell $1.99 (68%) to $0.93 on Friday after Huperzine A missed the primary endpoint of a significant improvement in ADAS-Cog scores for the low-dose group (200 ug twice daily)...